Panacea Biotec Ltd - Company Profile
Powered by 
All the sales intelligence you need on Panacea Biotec Ltd in one solution.
- Save hours of research time with a comprehensive
Sales Intelligence Solution.
- Understand how Panacea Biotec Ltd fits into your total
addressable market and Ideal Customer Profile.
- Gain competitive edge with triggers that tell you
when and how to engage with Panacea Biotec Ltd.
Get in touch about GlobalData Company reports
Contact the team or request a demo to find out how our data can drive your business forward
Panacea Biotec Ltd (Panacea) is a research-based biotechnology company. It is engaged in the research, development, manufacturing, and marketing of vaccines, pharmaceutical formulations, nutraceuticals, and nutritional products. The company’s pharmaceutical portfolio covers therapeutic areas such as hemorrhoids, piles, constipation, cold and cough, gastro-intestinal, nephrology, orthopedics, oncology, pain management, fever and diabetes. It also develops innovative adjuvants. Panacea’s pipeline products include the BPBC Betacoronavirus vaccine, NucoVac-11, DengiAll and a COVID-19 monoclonal antibody. The company operates in both domestic and international markets through its subsidiaries. Panacea is headquartered in New Delhi, India
Headquarters
India
Address
B-1 Extn / G-3, Mathura Road, Mohan Co-Opindlestate, New Delhi, 110044
Website
www.panaceabiotec.com
Telephone
91 11 41679000
No of Employees
1,290
Industry
Pharmaceuticals and Healthcare
Ticker Symbol & Exchange
PANACEABIO (NSE)
Revenue (2025)
$73.4M
14.4%
(2025 vs 2024)
EPS
XYZ
Net Income (2025)
XYZ
35.8%
(2025 vs 2024)
Market Cap*
$345.9M
Net Profit Margin (2025)
XYZ
44.0%
(2025 vs 2024)
* As of and is in US$
Panacea Biotec Ltd premium industry data and analytics
Products and Services
| Products | Services | Brands |
|---|---|---|
| Pharmaceutical Formulations (Therapeutic Areas): | Contract Research and Manufacturing | Sitcom |
| First in the World Innovations: Hemorrhoids, Piles and Constipation | Livoluk Fibre | |
| Diabetes | DapaBest | |
| XYZ | XYZ | |
| XYZ | XYZ | |
| XYZ | XYZ |
History
History section provides information on new products, mergers, acquisitions, expansions, approvals, and many more key events.
| Year | Event | Description |
|---|---|---|
| 2023 | New Products/Services | In December, the company launched the world’s first fully liquid wP-IPV-based Pentavalent vaccine, EasyFourPol, in India. |
| 2023 | Plans/Strategy | In March, the company introduced new facility at Biocon Park, Bengaluru. |
| 2022 | Asset Disposal | In March, the company sold its domestic formulation brands for India and Nepal to Mankind Pharma Ltd. |
Competitor Comparison
| Key Parameters | Panacea Biotec Ltd | Lupin Ltd | Zydus Lifesciences Ltd | GlaxoSmithKline Pharmaceuticals Ltd | Concord Biotech Ltd |
|---|---|---|---|---|---|
| Headquarters | India | India | India | India | India |
| City | New Delhi | Mumbai | Ahmedabad | Mumbai | Ahmedabad |
| State/Province | Delhi | Maharashtra | Gujarat | Maharashtra | Gujarat |
| No. of Employees | 1,290 | 19,021 | 23,283 | 3,103 | 1,571 |
| Entity Type | Public | Public | Public | Public | Public |
Key Financial Charts
Sales Growth
Net Income Growth
Executives
| Name | Position | Board | Since | Age |
|---|---|---|---|---|
| Dr. Rajesh Jain | Chairman; Managing Director | Executive Board | 1984 | 61 |
| Vinod Goel | Secretary; Chief Financial Officer; Head - Legal | Senior Management | 2025 | - |
| Ankesh Jain | Director | Executive Board | 2016 | 37 |
| Harshet Jain | Director | Executive Board | 2025 | - |
| Sandeep Jain | Joint Managing Director | Executive Board | 1984 | 59 |
| Non Dignissim Eros | Proin vel | Convallis | 2026 | XY |
| Non Dignissim Eros | Proin vel | Convallis | 2026 | XY |
| Non Dignissim Eros | Proin vel | Convallis | 2026 | XY |
Still looking?
Have you found what you were looking for? From start-ups to market leaders, uncover what they do and how they do it.
Explorer
Access more premium companies when you subscribe to Explorer